Related Experiment Video
Updated: Dec 23, 2025

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
COVID-19 in Children: Clinical Approach and Management
Jhuma Sankar1, Nitin Dhochak1, S K Kabra1
1Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Insights
The COVID-19 pandemic, caused by SARS-CoV-2, presents a significant global health challenge. While generally milder in children, severe illness can occur, necessitating prompt diagnosis and supportive care, with early intubation preferred for critical cases.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, is a global health crisis.
- Transmission occurs via respiratory droplets and contaminated surfaces.
- Children present with symptoms similar to other viral respiratory infections, but severity can vary.
Purpose of the Study:
- To outline the clinical presentation, diagnosis, and management of COVID-19 in children.
- To highlight the evolving nature of the disease in pediatric populations.
- To provide guidance on hospitalization, isolation, and treatment strategies.
Main Methods:
- Clinical observation and case reviews of pediatric COVID-19 patients.
- Review of diagnostic methods including RT-PCR.
- Analysis of current treatment guidelines and recommendations.
Main Results:
- COVID-19 in children is often milder than in adults, but infants and younger children may experience more severe illness.
- Diagnosis is confirmed via RT-PCR on respiratory specimens.
- Supportive care is the primary management; early intubation is recommended for severe cases to minimize aerosol generation.
Conclusions:
- While the case fatality rate in children is low, vigilance is required due to potential for severe disease.
- Prompt diagnosis and appropriate management, including isolation protocols, are crucial.
- No specific vaccines or chemotherapeutic agents are currently approved for pediatric COVID-19 treatment.
Abstract:
COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time. Transmission of the infection occurs by inhalation of infected droplets or direct contact with soiled surfaces and fomites. It should be suspected in all symptomatic children who have undertaken international travel in the last 14 d, all hospitalized children with severe acute respiratory illness, and asymptomatic direct and high-risk contacts of a confirmed case. Clinical symptoms are similar to any acute respiratory viral infection with less pronounced nasal symptoms. Disease seems to be milder in children, but situation appears to be changing. Infants and young children had relatively more severe illness than older children. The case fatality rate is low in children. Diagnosis can be confirmed by Reverse transcriptase - Polymerase chain reaction (RT-PCR) on respiratory specimen (commonly nasopharyngeal and oropharyngeal swab). Rapid progress is being made to develop rapid diagnostic tests, which will help ramp up the capacity to test and also reduce the time to getting test results. Management is mainly supportive care. In severe pneumonia and critically ill children, trial of hydroxychloroquine or lopinavir/ritonavir should be considered. As per current policy, children with mild disease also need to be hospitalized; if this is not feasible, these children may be managed on ambulatory basis with strict home isolation. Pneumonia, severe disease and critical illness require admission and aggressive management for acute lung injury and shock and/or multiorgan dysfunction, if present. An early intubation is preferred over non-invasive ventilation or heated, humidified, high flow nasal cannula oxygen, as these may generate aerosols increasing the risk of infection in health care personnel. To prevent post discharge dissemination of infection, home isolation for 1-2 wk may be advised. As of now, no vaccine or specific chemotherapeutic agents are approved for children.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Cystic Fibrosis: Management
Sinus disease and chronic...
Tonsillitis II: Management
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

